Exelixis, Inc. (EXEL)
46.61
+0.42
(+0.91%)
USD |
NASDAQ |
Dec 23, 16:00
46.62
+0.02
(+0.03%)
Pre-Market: 20:00
Exelixis SG&A Expense (TTM): 530.03M for Sept. 30, 2025
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Vanda Pharmaceuticals, Inc. | 214.26M |
| ADMA Biologics, Inc. | 96.37M |
| Aldeyra Therapeutics, Inc. | 9.186M |
| ACADIA Pharmaceuticals, Inc. | 523.36M |
| Axsome Therapeutics, Inc. | 514.57M |